TABLE 7.
Clinical and Pathologic Features of a Subset of FTLD-TDP Type A Cases With or Without GRN Mutations
| GRN Mutation | Sex | Clinical Dx | Death (Years) | Disease Duration (Years) | CDR Global | CDR Memory | CA1 Pathology |
|---|---|---|---|---|---|---|---|
| c.910_911insTG | F | PPA | 56 | 6.0 | 3 | 3 | Type 1 |
| c.102delC | F | PRAD | 62 | 7.0 | 3 | 3 | Type 1 |
| c.−8 + 3A>G | M | PPA | 70 | 4.0 | 3 | 3 | Type 1 |
| c.1317delC | M | FTD | 63 | 6.0 | 3 | 3 | Type 1 |
| c.1477C>T | F | PPA | 74 | 7.0 | 3 | 3 | Type 2 |
| – | F | FTD | 80 | 11 | 3 | 3 | Type 2 |
| – | M | LBD | 73 | 6 | 3 | 3 | Type 2 |
| - | F | PPA | 69 | 10 | 3 | 3 | Type 2 |
| – | F | PPA | 58 | 4 | 3 | 3 | Type 2 |
| – | F | PRAD | 84 | 9 | 3 | 3 | Type 2 |
| – | M | PRAD | 96 | 14 | 2 | 3 | Type 2 |
| – | M | CBS | 82 | 11 | 3 | 3 | Type 2 |
-, no GRN mutations.
CBD, corticobasal syndrome; CDR, Clinical Dementia Rating; FTD, frontotemporal dementia; LBD, Lewy body disease; PPA, primary progressive aphasia; PRAD, probable Alzheimer disease.